In this respect, treatment with MRS1220 reduced the transcripts of 29 genes that could tentatively favor the tumor phenotype; three targets that promote chemoresistance, LIMD1, TRIB2, and TGFB1, were distinguished. The gene discussed is LIMD1; the disease is neoplasm.